{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:55:19Z","timestamp":1787068519376,"version":"build-2736575974"},"reference-count":30,"publisher":"Elsevier BV","issue":"23","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Consejo Nacional de Ciencia y Tecnolog\u00eda (Mexico)","award":["Salud-2007-CO1-71241"],"award-info":[{"award-number":["Salud-2007-CO1-71241"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.vaccine.2017.04.027","type":"journal-article","created":{"date-parts":[[2017,4,28]],"date-time":"2017-04-28T19:45:30Z","timestamp":1493408730000},"page":"3116-3122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Antibody persistence in children aged 6\u20137  years one year following booster immunization with two MMR vaccines applied by aerosol or by injection"],"prefix":"10.1016","volume":"35","author":[{"given":"Jos\u00e9 Luis","family":"D\u00edaz Ortega","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deyanira","family":"Castaneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris Ma.","family":"Arellano Quintanilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silas P.","family":"Trumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Fern\u00e1ndez de Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.04.027_b0005","unstructured":"Pan American Health Organization. Plan of action for the documentation and verification of Measles, Rubella, and Congenital Rubella Syndrome elimination in the Region of the Americas. Comprehensive Family Immunization. Family Community Health Area. ISBN: 978-92-75-12992-0. Washington, D.C. 201."},{"key":"10.1016\/j.vaccine.2017.04.027_b0010","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/S0140-6736(99)95140-1","article-title":"Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: a randomized trial","volume":"355","author":"Dilraj","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.04.027_b0015","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.vaccine.2003.09.032","article-title":"Immunologic studies of specific mucosal and systemic immune responses in Mexican school children after booster aerosol or subcutaneous immunization with measles vaccine","volume":"22","author":"Bellanti","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.027_b0020","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/S0264-410X(02)00179-2","article-title":"A randomized trial demonstrating successful boosting responses following simultaneous aerosols of measles and rubella (MR) vaccines in school age children","volume":"20","author":"Sep\u00falveda-Amor","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.027_b0025","unstructured":"Bennett JV, Fern\u00e1ndez de Castro J, Valdespino JL, Garc\u00eda-Garc\u00eda ML, Islas-Romero R, Echaniz G, Sep\u00falveda-Amor J. Aerosols of measles-rubella vaccines induce better measles antibody booster responses than injected vaccines: randomized trials in Mexican school children. Bull WHO 2002;80:806\u201312."},{"key":"10.1016\/j.vaccine.2017.04.027_b0030","doi-asserted-by":"crossref","first-page":"4571","DOI":"10.1016\/j.vaccine.2009.05.086","article-title":"A new rapid and promising approach to aerosol immunization: inflatable bags and valved masks","volume":"27","author":"Bennett","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.027_b0035","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1016\/j.vaccine.2014.04.031","article-title":"Booster immune response in children of 6\u20137 years of age, randomly assigned to four groups with two MMR vaccines applied by aerosol or by injection","volume":"32","author":"D\u00edaz-Ortega","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.027_b0040","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.vaccine.2004.08.018","article-title":"Evaluation of immunogenicity and side effects of triple viral vaccine (MMR) in adults, given by two routes: subcutaneous and respiratory (aerosol)","volume":"23","author":"Fernandez de Castro","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.027_b0045","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.vaccine.2009.10.083","article-title":"Successful seroresponses to measles and rubella following aerosolized Triviraten vaccine, but poor response to aerosolized mumps (Rubini) component: comparisons with injected MMR","volume":"28","author":"Diaz-Ortega","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.027_b0050","doi-asserted-by":"crossref","first-page":"55","DOI":"10.4236\/wjv.2012.22008","article-title":"Safety and antibody responses to aerosolized MMR II vaccine in adults: an exploratory study","volume":"2","author":"D\u00edaz-Ortega","year":"2012","journal-title":"World J Vaccines"},{"key":"10.1016\/j.vaccine.2017.04.027_b0055","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1097\/00006454-200012000-00021","article-title":"Persistence of measles antibody two years after revaccination by aerosol or subcutaneous routes","volume":"19","author":"Dilraj","year":"2000","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2017.04.027_b0060","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1016\/j.vaccine.2007.03.003","article-title":"Aerosol and subcutaneous measles vaccine: measles antibody responses 6 years after re-vaccination","volume":"25","author":"Dilraj","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.027_b0065","doi-asserted-by":"crossref","first-page":"7228","DOI":"10.1016\/j.vaccine.2010.08.055","article-title":"Antibody persistence in young adults 1 year after MMR immunization by aerosol or by subcutaneous route","volume":"28","author":"D\u00edaz-Ortega","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.027_b0070","doi-asserted-by":"crossref","first-page":"S533","DOI":"10.1093\/infdis\/jir097","article-title":"Genetic characterization of measles vaccine strains","volume":"204","author":"Bankamp","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.04.027_b0075","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.vaccine.2007.10.046","article-title":"WHO working group on measles plaque reduction neutralization test. Plaque reduction neutralization test for measles antibodies: description of a standardized laboratory method for use in immunogenicity studies of aerosol vaccination","volume":"26","author":"Cohen","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.027_b0080","unstructured":"Behring. Enzygnost\u00ae Anti-Rubella-Virus\/IgG. Manual de Instrucciones; 2004."},{"key":"10.1016\/j.vaccine.2017.04.027_b0085","unstructured":"Behring. Enzygnost\u00ae Anti Parotitis-Virus\/IgG. Manual de Instrucciones; 2003."},{"key":"10.1016\/j.vaccine.2017.04.027_b0090","series-title":"Statistical methods for rates and proportions","author":"Fleiss","year":"2003"},{"key":"10.1016\/j.vaccine.2017.04.027_b0095","unstructured":"Mu\u00f1oz-Hern\u00e1ndez O, D\u00edaz-Ortega JL, Saltigeral P, Alvarez-Hern\u00e1ndez L, Alvarez y Mu\u00f1oz MT, Hern\u00e1ndez-Porras M, Sol\u00f3rzano-Santos F. Informe final de la Comisi\u00f3n para la Documentaci\u00f3n y Verificaci\u00f3n de la Eliminaci\u00f3n del Sarampi\u00f3n, Rub\u00e9ola y S\u00edndrome de Rub\u00e9ola Cong\u00e9nita en M\u00e9xico. Available online at: <https:\/\/pftp.paho.org\/Public\/FCH\/IM\/Elimination\/Informes%20de%20paises\/Informe_final_16feb2012_Mexico.pdf>."},{"key":"10.1016\/j.vaccine.2017.04.027_b0100","doi-asserted-by":"crossref","first-page":"79","DOI":"10.4236\/wjv.2015.52010","article-title":"Multinational measles outbreak in post-elimination era, involves three countries of North America and a European country in a short transmission chain","volume":"5","author":"Ruiz-Matus","year":"2015","journal-title":"World J Vaccines"},{"key":"10.1016\/j.vaccine.2017.04.027_b0105","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1016\/j.vaccine.2013.02.047","article-title":"A systematic review of rubella vaccination strategies implemented in the Americas: impact on the incidence and seroprevalence rates ofrubellaand congenitalrubellas\u00edndrome","volume":"17","author":"Mongua-Rodriguez","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.027_b0110","unstructured":"Direcci\u00f3n General de Epidemiolog\u00eda. Casos probables de Parotiditis infecciosa (B26) por grupos de edad Estados Unidos Mexicanos 2010 y 2011. Available at: <http:\/\/www.epidemiologia.salud.gob.mx\/anuario\/html\/anuarios.html>."},{"key":"10.1016\/j.vaccine.2017.04.027_b0115","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/infdis\/162.5.1036","article-title":"Measles antibody: reevaluation of protective titers","volume":"162","author":"Chen","year":"1990","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.04.027_b0120","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/ajcp\/106.2.170","article-title":"Rubella immunity. Defining the level of protective antibody","volume":"106","author":"Skendzel","year":"1996","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.vaccine.2017.04.027_b0125","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1017\/S0950268807008266","article-title":"Standardization of measles, mumps and rubella assays to enable comparisons of seroprevalence data across 21 European countries and Australia","volume":"135","author":"Tischer","year":"2007","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2017.04.027_b0130","doi-asserted-by":"crossref","first-page":"4847","DOI":"10.1128\/JCM.43.9.4847-4851.2005","article-title":"Mumps virus-specific antibody titers from pre-vaccine era sera: comparison of the plaque reduction neutralization assay and enzyme immunoassays","volume":"43","author":"Mauldin","year":"2005","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2017.04.027_b0135","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1086\/588197","article-title":"Long-term persistence of mumps antibody after receipt of 2 measles-mumps-rubella (MMR) vaccinations and antibody response after a third MMR vaccination among a university population","volume":"197","author":"Date","year":"2008","journal-title":"JID"},{"key":"10.1016\/j.vaccine.2017.04.027_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.biologicals.2012.03.002","article-title":"Aerosolized MMR vaccine: evaluating potential transmission of components to vaccine administrators and contacts of vaccinees","author":"Diaz-Ortega","year":"2012","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2017.04.027_b0145","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1407417","article-title":"A randomized, controlled trial of an aerosolized vaccine against measles","volume":"372","author":"Low","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.04.027_b0150","first-page":"449","article-title":"La vacunaci\u00f3n contra el sarampi\u00f3n. Situaci\u00f3n en M\u00e9xico y Am\u00e9rica. Avances en el m\u00e9todo de inmunizaci\u00f3n por aerosol","volume":"47","author":"Fern\u00e1ndez de Castro","year":"1990","journal-title":"Bol Med Hosp Infant Mex"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17305017?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17305017?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,6,25]],"date-time":"2018-06-25T08:39:53Z","timestamp":1529915993000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17305017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":30,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0264410X17305017"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.04.027","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody persistence in children aged 6\u20137years one year following booster immunization with two MMR vaccines applied by aerosol or by injection","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.04.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}